eribulin mesylate,ecteribulin,farletuzumab
bms,eisai pharmaceutical
['eribulin', 'farletuzumab', 'farletuzumab,ecteribulin', 'eisai']
eisai presents new findings for antibody drug conjugate farletuzumab ecteribulin at 2022 asco annual meeting #stocksmarket #pressrelease
Join us at https://t.co/9QZSYoqhvl - Stock Market News and Press Releases. #StockMarket - As an affiliate, we earn from qualifying purchases.